WARPTECHNEWS · LAB
HomeAIBusinessTechArchive
WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

  • Home
  • Archivio
  • Editor's Brief
  • Cerca
  • Il tuo account
  • Newsletter tech/AI

Informazioni legali

  • Privacy Policy
  • Termini di servizio
  • Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Home
Storia in 2 fonti

Aurobindo Pharma’s Q4 net up 2% to ₹921 crore

Aurobindo Pharma reports a 2% net profit rise to ₹921 crore with total revenue growing 5.6% to ₹8,853 crore in Q4.

Raccontata dathehindubusinessline.comthehindu.com

Confronto fonti

2 prospettive sulla stessa storia
AI · summaries
thehindubusinessline.comStai leggendo1 mesi fa

Aurobindo Pharma’s Q4 net up 2% to ₹921 crore

Aurobindo Pharma reports a 2% net profit rise to ₹921 crore with total revenue growing 5.6% to ₹8,853 crore in Q4.

originale
thehindu.com1 mesi fa

Aurobindo Pharma Q4 net up 2% to ₹921 cr

Aurobindo Pharma reports Q4 net profit rise to ₹921 crore, driven by strong European market performance and overall revenue growth.

Leggi questa versione → originale

Timeline cronologica

  1. giovedì 21 maggio 2026·thehindubusinessline.com

    Aurobindo Pharma’s Q4 net up 2% to ₹921 crore

    Aurobindo Pharma reports a 2% net profit rise to ₹921 crore with total revenue growing 5.6% to ₹8,853 crore in Q4.

  2. giovedì 21 maggio 2026·thehindu.com

    Aurobindo Pharma Q4 net up 2% to ₹921 cr

    Aurobindo Pharma reports Q4 net profit rise to ₹921 crore, driven by strong European market performance and overall revenue growth.

venerdì 22 maggio 2026·thehindubusinessline.com

Aurobindo Pharma edges past Dr Reddy’s in FY26 revenue race

Aurobindo Pharma surpasses Dr Reddy's in FY26 revenue, becoming the second-largest Indian pharma company.